A Randomized Controlled Dose-Escalation Study of LY06006, a Recombinant Humanized Monoclonal Antibody to RANKL, in Chinese Healthy Adults

A Randomized Controlled Dose-Escalation Study of LY06006, a Recombinant Humanized Monoclonal Antibody to RANKL, in Chinese Healthy Adults

Background: This study was conducted to explore the safety, tolerance, pharmacokinetics, pharmacodynamics, and immunogenicity of LY06006, a recombinant humanized monoclonal antibody to RANKL, when administrated subcutaneously in Chinese healthy adults.Research design and methods: This was a randomiz...

Full description

Bibliographic Details
Main Authors: Suping Niu, Min Chen, Diqin Yan, Xiangxing Liu, Shuren Guo, Lun Ou, Huaying Fan, Jie Lv, Qian Wang, Wenliang Dong, Lin Xia, Simin Wang, Gang Liu, Qun Gu, Danjie Guo, Hongxia Liu, Huiying Rao, Qingshan Zheng, Xiaoyan Nie, Haifeng Song, Yi Fang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Pharmacology
Subjects:
pharmacokinetics
pharmacodynamics
immunogenicity
denosumab
RANK/RANKL
osteoporosis
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.893166/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.893166/full

Similar Items